Nele Myngheer1, Karel Allegaert2, Andrew Hattersley3, Tim McDonald3, Holger Kramer4, Frances M Ashcroft4, Johan Verhaeghe5, Chantal Mathieu6, Kristina Casteels7. 1. Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium. 2. Neonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium Department of Development and Regeneration, KU Leuven, Leuven, Belgium. 3. University of Exeter Medical School, Exeter, U.K. 4. University Laboratory of Physiology, Oxford, Oxford, U.K. 5. Department of Obstetrics/Gynaecology, University Hospitals Leuven, Leuven, Belgium. 6. Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium. 7. Department of Development and Regeneration, KU Leuven, Leuven, Belgium Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium kristina.casteels@uzleuven.be.
Abstract
OBJECTIVE: Sulfonylureas (SUs) are effective at controlling glycemia in permanent neonatal diabetes mellitus (PNDM) caused by KCNJ11 (Kir6.2) mutations. RESEARCH DESIGN AND METHODS: We report the case of a woman with PNDM who continued high doses of glibenclamide (85 mg/day) during her pregnancy. The baby was born preterm, and presented with macrosomia and severe hyperinsulinemic hypoglycemia requiring high-rate intravenous glucose infusion. RESULTS: Postnatal genetic testing excluded a KCNJ11 mutation in the baby. Glibenclamide was detected in both the baby's blood and the maternal milk. CONCLUSIONS: We hypothesize that high doses of glibenclamide in the mother led to transplacental passage of the drug and overstimulation of fetal β-cells, which resulted in severe hyperinsulinemic hypoglycemia in the neonate (who did not carry the mutation) and contributed to fetal macrosomia. We suggest that glibenclamide (and other SUs) should be avoided in mothers with PNDM if the baby does not carry the mutation or if prenatal screening has not been performed, while glibenclamide may be beneficial when the fetus is a PNDM carrier.
OBJECTIVE:Sulfonylureas (SUs) are effective at controlling glycemia in permanent neonatal diabetes mellitus (PNDM) caused by KCNJ11 (Kir6.2) mutations. RESEARCH DESIGN AND METHODS: We report the case of a woman with PNDM who continued high doses of glibenclamide (85 mg/day) during her pregnancy. The baby was born preterm, and presented with macrosomia and severe hyperinsulinemic hypoglycemia requiring high-rate intravenous glucose infusion. RESULTS: Postnatal genetic testing excluded a KCNJ11 mutation in the baby. Glibenclamide was detected in both the baby's blood and the maternal milk. CONCLUSIONS: We hypothesize that high doses of glibenclamide in the mother led to transplacental passage of the drug and overstimulation of fetal β-cells, which resulted in severe hyperinsulinemic hypoglycemia in the neonate (who did not carry the mutation) and contributed to fetal macrosomia. We suggest that glibenclamide (and other SUs) should be avoided in mothers with PNDM if the baby does not carry the mutation or if prenatal screening has not been performed, while glibenclamide may be beneficial when the fetus is a PNDM carrier.
Authors: Ewan R Pearson; Isabelle Flechtner; Pål R Njølstad; Maciej T Malecki; Sarah E Flanagan; Brian Larkin; Frances M Ashcroft; Iwar Klimes; Ethel Codner; Violeta Iotova; Annabelle S Slingerland; Julian Shield; Jean-Jacques Robert; Jens J Holst; Penny M Clark; Sian Ellard; Oddmund Søvik; Michel Polak; Andrew T Hattersley Journal: N Engl J Med Date: 2006-08-03 Impact factor: 91.245
Authors: Tomasz Klupa; Elzbieta Kozek; Natalia Nowak; Katarzyna Cyganek; Agnieszka Gach; Tomasz Milewicz; Krzysztof Czajkowski; Justyna Tolloczko; Wojciech Mlynarski; Maciej T Malecki Journal: J Clin Endocrinol Metab Date: 2010-05-13 Impact factor: 5.958
Authors: Anna L Gloyn; Ewan R Pearson; Jennifer F Antcliff; Peter Proks; G Jan Bruining; Annabelle S Slingerland; Neville Howard; Shubha Srinivasan; José M C L Silva; Janne Molnes; Emma L Edghill; Timothy M Frayling; I Karen Temple; Deborah Mackay; Julian P H Shield; Zdenek Sumnik; Adrian van Rhijn; Jerry K H Wales; Penelope Clark; Shaun Gorman; Javier Aisenberg; Sian Ellard; Pål R Njølstad; Frances M Ashcroft; Andrew T Hattersley Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Zsolt Gaal; Tomasz Klupa; Irene Kantor; Wojciech Mlynarski; Laszlo Albert; Justyna Tolloczko; Istvan Balogh; Krzysztof Czajkowski; Maciej T Malecki Journal: Diabetes Care Date: 2012-06 Impact factor: 19.112
Authors: M F Hebert; X Ma; S B Naraharisetti; K M Krudys; J G Umans; G D V Hankins; S N Caritis; M Miodovnik; D R Mattison; J D Unadkat; E J Kelly; D Blough; C Cobelli; M S Ahmed; W R Snodgrass; D B Carr; T R Easterling; P Vicini Journal: Clin Pharmacol Ther Date: 2009-03-18 Impact factor: 6.903
Authors: Elisa De Franco; Cécile Saint-Martin; Klaus Brusgaard; Amy E Knight Johnson; Lydia Aguilar-Bryan; Pamela Bowman; Jean-Baptiste Arnoux; Annette Rønholt Larsen; May Sanyoura; Siri Atma W Greeley; Raúl Calzada-León; Bradley Harman; Jayne A L Houghton; Elisa Nishimura-Meguro; Thomas W Laver; Sian Ellard; Daniela Del Gaudio; Henrik Thybo Christesen; Christine Bellanné-Chantelot; Sarah E Flanagan Journal: Hum Mutat Date: 2020-02-17 Impact factor: 4.878
Authors: Katrien Benhalima; Karolien Robyns; Paul Van Crombrugge; Natascha Deprez; Bruno Seynhave; Roland Devlieger; Johan Verhaeghe; Chantal Mathieu; Frank Nobels Journal: BMC Pregnancy Childbirth Date: 2015-10-23 Impact factor: 3.007
Authors: Susan M O'Connell; Peter Proks; Holger Kramer; Katia K Mattis; Gregor Sachse; Caroline Joyce; Jayne A L Houghton; Sian Ellard; Andrew T Hattersley; Frances M Ashcroft; Stephen M P O'Riordan Journal: Clin Case Rep Date: 2015-09-08